FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1467736063> ?p ?o ?g. }

• W1467736063 abstract "Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. Significant morbidity can be associated with severe cases of Bell's palsy.To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy.On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, DARE, NHS EED, and HTA. We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies.We considered randomised controlled trials or quasi-randomised controlled trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that had a high risk of bias in several domains.Pairs of authors independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures.Eleven trials, including 2883 participants, met the inclusion criteria and are included in the final analysis. We added four studies to the previous review for this update. Some of the trials were small, and a number were at high or unclear risk of bias. Other trials did not meet current best standards in allocation concealment and blinding. Incomplete recoveryWe found no significant benefit from adding antivirals to corticosteroids in comparison with corticosteroids alone for people with Bell's palsy (risk ratio (RR) 0.69, 95% confidence interval (CI) 0.47 to 1.02, n = 1715). For people with severe Bell's palsy (House-Brackmann scores of 5 and 6 or the equivalent in other scales), we found a reduction in the rate of incomplete recovery at month six when antivirals plus corticosteroids were used (RR 0.64, 95% CI 0.41 to 0.99, n = 478). The outcome for the participants receiving corticosteroids alone was significantly better than for those receiving antivirals alone (RR 2.09, 95% CI 1.36 to 3.20, n = 1169). The treatment effect of placebo was significantly lower than that of antivirals plus corticosteroids (RR 0.56, 95% CI 0.41 to 0.76, n = 658). Antivirals alone had a non-significant detrimental effect on the outcome compared with placebo (RR 1.10, 95% CI 0.87 to 1.40, n = 658). Motor synkinesis or crocodile tearsIn three trials comparing antivirals and corticosteroids with corticosteroids and placebo that assessed this outcome, we found a significant difference in long-term sequelae in favour or antivirals plus corticosteroids (RR 0.73, 95% CI 0.54 to 0.99, n = 869). Three trials comparing antivirals alone with corticosteroids alone investigating this outcome showed fewer sequelae with corticosteroids (RR 1.44, 95% CI 1.11 to 1.85, n = 873). We found no data on long-term sequelae for other comparisons. Adverse events Adverse event data were available in three studies giving comparison data on 1528 participants. None of the four comparisons (antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment; antivirals versus corticosteroids; antivirals plus corticosteroids versus placebo; antivirals versus placebo) showed significant differences in adverse events between treatment and control arms. We could find no correlation with specific treatment within these results.Moderate-quality evidence from randomised controlled trials showed no additional benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone or with placebo, and no benefit from antivirals alone compared to placebo, for the treatment of Bell's palsy. Moderate-quality evidence showed a small but just significant benefit of combination therapy compared with corticosteroids alone in severe Bell's palsy. We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids." @default.
• W1467736063 created "2016-06-24" @default.
• W1467736063 creator A5004722239 @default.
• W1467736063 creator A5022607182 @default.
• W1467736063 creator A5035747300 @default.
• W1467736063 creator A5040776267 @default.
• W1467736063 creator A5054987821 @default.
• W1467736063 creator A5059322051 @default.
• W1467736063 creator A5081796247 @default.
• W1467736063 date "2015-05-04" @default.
• W1467736063 modified "2023-10-10" @default.
• W1467736063 title "Antiviral treatment for Bell's palsy (idiopathic facial paralysis)" @default.
• W1467736063 cites W141818334 @default.
• W1467736063 cites W1502752408 @default.
• W1467736063 cites W1822431265 @default.
• W1467736063 cites W1964500391 @default.
• W1467736063 cites W1980683964 @default.
• W1467736063 cites W1982893048 @default.
• W1467736063 cites W1989569051 @default.
• W1467736063 cites W1995354841 @default.
• W1467736063 cites W1995751102 @default.
• W1467736063 cites W1995858799 @default.
• W1467736063 cites W1996078518 @default.
• W1467736063 cites W2036824495 @default.
• W1467736063 cites W2037588066 @default.
• W1467736063 cites W2038449210 @default.
• W1467736063 cites W2039932936 @default.
• W1467736063 cites W2044345542 @default.
• W1467736063 cites W2063572562 @default.
• W1467736063 cites W2075551782 @default.
• W1467736063 cites W2076959351 @default.
• W1467736063 cites W2084038992 @default.
• W1467736063 cites W2101697605 @default.
• W1467736063 cites W2106852126 @default.
• W1467736063 cites W2107664743 @default.
• W1467736063 cites W2109669064 @default.
• W1467736063 cites W2114831029 @default.
• W1467736063 cites W2124168198 @default.
• W1467736063 cites W2137371191 @default.
• W1467736063 cites W2142273169 @default.
• W1467736063 cites W2156798246 @default.
• W1467736063 cites W2157823046 @default.
• W1467736063 cites W2160697719 @default.
• W1467736063 cites W2165808468 @default.
• W1467736063 cites W2316705304 @default.
• W1467736063 cites W2913542543 @default.
• W1467736063 cites W4241384504 @default.
• W1467736063 cites W4243397083 @default.
• W1467736063 cites W2060328814 @default.
• W1467736063 doi "https://doi.org/10.1002/14651858.cd001869.pub5" @default.
• W1467736063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26343420" @default.
• W1467736063 hasPublicationYear "2015" @default.
• W1467736063 type Work @default.
• W1467736063 sameAs 1467736063 @default.
• W1467736063 citedByCount "33" @default.
• W1467736063 countsByYear W14677360632015 @default.
• W1467736063 countsByYear W14677360632016 @default.
• W1467736063 countsByYear W14677360632017 @default.
• W1467736063 countsByYear W14677360632019 @default.
• W1467736063 countsByYear W14677360632020 @default.
• W1467736063 crossrefType "reference-entry" @default.
• W1467736063 hasAuthorship W1467736063A5004722239 @default.
• W1467736063 hasAuthorship W1467736063A5022607182 @default.
• W1467736063 hasAuthorship W1467736063A5035747300 @default.
• W1467736063 hasAuthorship W1467736063A5040776267 @default.
• W1467736063 hasAuthorship W1467736063A5054987821 @default.
• W1467736063 hasAuthorship W1467736063A5059322051 @default.
• W1467736063 hasAuthorship W1467736063A5081796247 @default.
• W1467736063 hasBestOaLocation W14677360631 @default.
• W1467736063 hasConcept C126322002 @default.
• W1467736063 hasConcept C141071460 @default.
• W1467736063 hasConcept C142724271 @default.
• W1467736063 hasConcept C168563851 @default.
• W1467736063 hasConcept C1862650 @default.
• W1467736063 hasConcept C187212893 @default.
• W1467736063 hasConcept C204787440 @default.
• W1467736063 hasConcept C2771230 @default.
• W1467736063 hasConcept C2776775940 @default.
• W1467736063 hasConcept C2778097013 @default.
• W1467736063 hasConcept C2781019609 @default.
• W1467736063 hasConcept C2908643374 @default.
• W1467736063 hasConcept C44249647 @default.
• W1467736063 hasConcept C535046627 @default.
• W1467736063 hasConcept C71924100 @default.
• W1467736063 hasConcept C82789193 @default.
• W1467736063 hasConceptScore W1467736063C126322002 @default.
• W1467736063 hasConceptScore W1467736063C141071460 @default.
• W1467736063 hasConceptScore W1467736063C142724271 @default.
• W1467736063 hasConceptScore W1467736063C168563851 @default.
• W1467736063 hasConceptScore W1467736063C1862650 @default.
• W1467736063 hasConceptScore W1467736063C187212893 @default.
• W1467736063 hasConceptScore W1467736063C204787440 @default.
• W1467736063 hasConceptScore W1467736063C2771230 @default.
• W1467736063 hasConceptScore W1467736063C2776775940 @default.
• W1467736063 hasConceptScore W1467736063C2778097013 @default.
• W1467736063 hasConceptScore W1467736063C2781019609 @default.
• W1467736063 hasConceptScore W1467736063C2908643374 @default.
• W1467736063 hasConceptScore W1467736063C44249647 @default.
• W1467736063 hasConceptScore W1467736063C535046627 @default.
• W1467736063 hasConceptScore W1467736063C71924100 @default.

• next